000			02134cam a2200337 a 4500
003			EG-GiCUC
005			20250223032226.0
008			190313s2018 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.12.21.M.Sc.2018.Ah.E
100	0		_aAhmed Motawa Eisa Elhouseini
245	1	0	_aEvaluation of interleukin-10 and transforming growth factor-Ý in human hepatocellular carcinoma cell line subjected to "sorafenib-taurine" therapeutic model / _cAhmed Motawa Eisa Elhouseini ; Supervised Ahmed Mohamed Fathi Afifi , Reda Hasan Tabashy , Mohamed Ahmed Khalil
246	1	5	_aتقييم " الانترلوكين-10" و" عامل النمو التحويلي - بيتا" في خلايا الكبد السرطاني الخبيث للأنسان بعد التعرض للنموذج العلاجي " سورافينيب - تاورين
260			_aCairo : _bAhmed Motawa Eisa Elhouseini , _c2018
300			_a101 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Science - Department of Zoology
520			_aSorafenib (Sor) is a multi-kinase inhibitor, it is recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, Sor has severe and marked side effects. Taurine (Tau) has been shown to enhance the therapeutic effects of cancer chemotherapy and also to enhance the function of leukocytes. Aim of the study: The present study aimed to investigate the immunological aspects of Sor, Taurine as well as after combination on human hepatocytes. Materials and Methods: HepG2 cell line was cultured to determine IC50 using SRB assay. The levels of TGF-Ý and IL-10 released in culture media of the cells were determined by ELISA
530			_aIssued also as CD
653		4	_aHepG2
653		4	_aSorafenib
653		4	_aTaurine
700	0		_aAhmed Mohamed Fathi Afifi , _eSupervisor
700	0		_aReda Hasan Tabashy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c70835 _d70835